Hetero Drugs
Hetero Drugs Limited, commonly referred to as Hetero, is a prominent player in the global pharmaceutical industry, headquartered in Hyderabad, India. Established in 1993, the company has made significant strides in the development and manufacturing of a diverse range of generic and branded medications, particularly in the areas of anti-retrovirals, oncology, and cardiovascular treatments. With a strong presence in over 120 countries, Hetero is recognised for its commitment to quality and affordability, making essential medicines accessible to patients worldwide. The company’s extensive portfolio includes over 200 products, distinguished by their rigorous quality standards and innovative formulations. Hetero's dedication to research and development has positioned it as a leader in the pharmaceutical sector, contributing to its reputation for excellence and reliability in healthcare solutions.
DitchCarbon Score
How does Hetero Drugs's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hetero Drugs's score of 9 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Hetero Drugs's reported carbon emissions
In 2023, Hetero Drugs reported total carbon emissions of approximately 412,461,000 kg CO2e, with Scope 1 emissions at about 213,330,000 kg CO2e and Scope 2 emissions at approximately 199,131,000 kg CO2e. This marks a slight decrease from 2022, where total emissions were around 472,571,000 kg CO2e. Hetero Drugs has set ambitious climate commitments, aspiring for net-zero emissions by 2045. The company aims to reduce its carbon emissions from Scope 1 and 2 by 25% by 2030, using 2022 as the baseline year. This commitment aligns with their long-term strategy to address climate change and reduce their overall carbon footprint. The company is also committed to the Science Based Targets initiative (SBTi), with a long-term target to achieve net-zero emissions across all scopes by 2050. Hetero Drugs is actively working towards these goals, reflecting a strong commitment to sustainability within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 339,647,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 22,000 | 00,000 | 00,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hetero Drugs is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
